Company:  ALNYLAM PHARMACEUTICALS, ... (ALNY)
Form Type:  8-K
Filing Date:  1/14/2013 
CIK:  0001178670 
Address:  300 THIRD STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  (617) 551-8200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$52.78  
Change: 
-1.54 (-2.84%)  
Trade Time: 
Apr 24  
Market Cap: 
$3.49B
Description of Business
We are a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. We believe that drugs that work through RNAi have the potential to become a broad new class of drugs, like small molecule, protein and antibody drugs. Using our intellectual property and the expertise we have built in RNAi, we are developing a set of biological and chemical methods and know-how that we apply in a systematic way to develop RNAi therapeutics for a variety of diseases.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 99.1
BROKERAGE PARTNERS